Literature DB >> 16333033

Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis.

Alison K Bauer1, Darlene Dixon, Laura M DeGraff, Hye-Youn Cho, Christopher R Walker, Alvin M Malkinson, Steven R Kleeberger.   

Abstract

Because chronic pulmonary diseases predispose to lung neoplasia, the identification of the molecular mechanisms involved could provide novel preventive, diagnostic, and therapeutic strategies. Toll-like receptors (TLRs) transduce exogenous and endogenous signals into the production of inflammatory cytokines to coordinate adaptive immune responses. To determine the role of Tlr4 in chronic lung inflammation, we compared lung permeability, leukocyte infiltration, and nuclear factor kappa B (NFkappaB) and activator protein 1 (AP-1) DNA binding in butylated hydroxytoluene (BHT)-treated (four weekly injections of 125-200 mg/kg each) inbred mouse strains with functional Tlr4 (OuJ and BALB) and mutated Tlr4 (HeJ and BALB(Lps-d)). We also measured primary tumor formation in these mice after single-carcinogen injection (3-methylcholanthrene; 10 microg/kg), followed by BHT treatment (six weekly injections of 125-200 mg/kg each). Mice with functional Tlr4 had reduced lung permeability, leukocyte inflammation, and primary tumor formation (BALB(Lps-d), mean = 22.3 tumors/mouse, versus BALB, mean = 13.9 tumors/mouse, difference = 8.4 tumors/mouse, 95% confidence interval = 4.6 to 12.1 tumors/mouse; P = .025) compared with mice with mutated Tlr4. NFkappaB DNA binding activity was higher in OuJ than in HeJ mice; however, AP-1 activity was elevated in HeJ mice. To our knowledge, this is the first model to demonstrate a modulatory role for Tlr4 in chronic lung inflammation and tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16333033     DOI: 10.1093/jnci/dji403

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  35 in total

1.  Mouse pulmonary dose- and time course-responses induced by exposure to nitrogen-doped multi-walled carbon nanotubes.

Authors:  Dale W Porter; Marlene Orandle; Peng Zheng; Nianqiang Wu; Raymond F Hamilton; Andrij Holian; Bean T Chen; Michael Andrew; Michael G Wolfarth; Lori Battelli; Shuji Tsuruoka; Mauricio Terrones; Vince Castranova
Journal:  Inhal Toxicol       Date:  2020-02-07       Impact factor: 2.724

2.  Differential innate immune cell signatures and effects regulated by toll-like receptor 4 during murine lung tumor promotion.

Authors:  Carla-Maria Alexander; Ka-Na Xiong; Kalpana Velmurugan; Julie Xiong; Ross S Osgood; Alison K Bauer
Journal:  Exp Lung Res       Date:  2016-04       Impact factor: 2.459

Review 3.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.

Authors:  Mao Wang; Alex Gauthier; LeeAnne Daley; Katelyn Dial; Jiaqi Wu; Joanna Woo; Mosi Lin; Charles Ashby; Lin L Mantell
Journal:  Antioxid Redox Signal       Date:  2019-07-11       Impact factor: 8.401

4.  Resveratrol enhances cell-mediated immune response to DMBA through TLR4 and prevents DMBA induced cutaneous carcinogenesis.

Authors:  Nabiha Yusuf; Tahseen H Nasti; Sreelatha Meleth; Craig A Elmets
Journal:  Mol Carcinog       Date:  2009-08       Impact factor: 4.784

5.  Vanadium pentoxide induces pulmonary inflammation and tumor promotion in a strain-dependent manner.

Authors:  Elizabeth A Rondini; Dianne M Walters; Alison K Bauer
Journal:  Part Fibre Toxicol       Date:  2010-04-12       Impact factor: 9.400

6.  Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion.

Authors:  Huan Yang; Huiqin Zhou; Ping Feng; Xiaoni Zhou; Huiyan Wen; Xiaofang Xie; Haiying Shen; Xueming Zhu
Journal:  J Exp Clin Cancer Res       Date:  2010-07-10

Review 7.  TLR agonists: our best frenemy in cancer immunotherapy.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Eduardo Davila
Journal:  J Leukoc Biol       Date:  2013-03-08       Impact factor: 4.962

8.  Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma.

Authors:  Donghua Xu; Xiaochen Wang; Shushan Yan; Yin Yin; Jiajie Hou; Xuehao Wang; Beicheng Sun
Journal:  Tumour Biol       Date:  2014-07-18

9.  Transcriptomic analysis of pathways regulated by toll-like receptor 4 in a murine model of chronic pulmonary inflammation and carcinogenesis.

Authors:  Alison K Bauer; Jennifer Fostel; Laura M Degraff; Elizabeth A Rondini; Christopher Walker; Sherry F Grissom; Julie Foley; Steven R Kleeberger
Journal:  Mol Cancer       Date:  2009-11-19       Impact factor: 27.401

10.  Down-regulation of Toll-like receptor 4 gene expression by short interfering RNA attenuates bone cancer pain in a rat model.

Authors:  Liu Si Lan; Yang Jian Ping; Wang Li Na; Jiang Miao; Qiu Qiao Cheng; Ma Zhen Ni; Liu Lei; Li Cai Fang; Ren Chun Guang; Zhou Jin; Li Wei
Journal:  Mol Pain       Date:  2010-01-20       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.